hotspot -WSS

hotspot

author：entertainment 2025-09-30 18:55:23 - browse：81342

An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT — Christine Kao/STAT

It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

Lobbying power of AI, software-enabled devices

Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： EU regulator recommends expanding Mounjaro approval to obesity

explore

entertainment

WSS

J&J expands global access to TB drug amid advocacy campaign

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

Medicare Advantage today, explained in one chart

Argenx drug significantly slows progression of nerve disorder

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Woman gored by Bison at Yellowstone

hotspot

hotspot

Lobbying power of AI, software-enabled devices

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Francis Collins on trust in science and how Covid communications failed

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Wildfire smoke exposes gaps in outdoor worker protections

Medicare Advantage today, explained in one chart

Activists slam private health insurers over coverage restrictions

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Heart attack and stroke risk calculators need revising

Prior authorization will have to move faster under new Biden rule

focus

Argenx drug significantly slows progression of nerve disorder

EU regulator recommends expanding Mounjaro approval to obesity

The tragedy of Johnson & Johnson’s Covid vaccine

Involuntary treatment for addiction doesn't work

Prior authorization will have to move faster under new Biden rule

Congress likely to miss an opportunity to fix drug shortages issue

explore

hotspot

entertainment

focus